Bradley S. Galer
Director/Board Member bij Zogenix International Ltd.
Profiel
Bradley S.
Galer is currently a Director at Zogenix International Ltd.
He was previously the President-Pain Group at Nuvo Pharmaceuticals, Inc. from 2009 to 2013.
From 2013 to 2022, he served as the Chief Medical Officer & Executive Vice President at Zogenix, Inc. Prior to that, he was the Senior Medical Officer & VP-Scientific Affairs at Endo Pharmaceuticals, Inc. from 2002 to 2005.
Galer holds a doctorate degree from Albert Einstein College of Medicine, Inc.
Actieve functies van Bradley S. Galer
Bedrijven | Functie | Begin |
---|---|---|
Zogenix International Ltd.
Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Director/Board Member | 15-08-2016 |
Eerdere bekende functies van Bradley S. Galer
Bedrijven | Functie | Einde |
---|---|---|
ZOGENIX, INC. | Chief Tech/Sci/R&D Officer | 01-06-2022 |
NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 01-12-2013 |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | Chief Tech/Sci/R&D Officer | 01-10-2005 |
Opleiding van Bradley S. Galer
Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Nuvo Pharmaceuticals, Inc.
Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Zogenix, Inc.
Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | Health Technology |
Zogenix International Ltd.
Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |